Public Health Impact of the MVA-BN Vaccine During the 2022 Mpox Outbreak: A Systematic Review.

ABSTRACT:

Background/objectives

Previously endemic to sub-Saharan Africa, mpox has since emerged globally, resulting in more than 150,000 cases in over 100 countries in the 2022 outbreak. The Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is licensed and recommended for at-risk populations in many countries and received World Health Organization (WHO) pre-qualification in September 2024.

Methods

We conducted this systematic literature review (SLR) to compare analyses, published from 2022 through 2024, of cases averted due to mpox vaccination during the 2022 outbreak to assess the feasibility of estimating the impact on the United States (US). The search included studies that utilized reported case data from any country.

Results

Nine studies were identified. Four esti

SUBMITTER: Katsandres SC 

PROVIDER: S-EPMC12564786 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature